Stock Events

Valneva 

€3.18
5
-€0.05-1.42% Today

Statistics

Day High
3.25
Day Low
3.16
52W High
8
52W Low
3.16
Volume
2,198
Avg. Volume
2,135
Mkt Cap
650.06M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

21MarExpected
Q1 2022
Q2 2022
Q3 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
-2.68
-1.47
-0.26
0.95
Expected EPS
0.6145
Actual EPS
0

People Also Follow

This list is based on the watchlists of people on Stock Events who follow VLA.VI. It's not an investment recommendation.

About

Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trial against Borrelia; and VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is headquartered in Saint-Herblain, France.
Show more...
CEO
Mr. Thomas Lingelbach
Employees
762
Country
FR
ISIN
FR0004056851
WKN
000A0MVJZ

Listings